OBJECTIVE: Some ingestible complementary and alternative medicine (CAM) supplements, including herbal remedies, teas, and vitamins, have biological activities that make them likely to interact poorly with conventional chemotherapeutic treatments. This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together. METHODS: A total of 219 patients with ovarian cancer who received care from 1 of 2 participating conventional oncology practices were surveyed about CAM use during and after ovarian cancer treatment. RESULTS: A total of 200 women reported having chemotherapy to treat their ovarian cancer. Of those, 79 (40%) reported using 1 or more CAM supplements that could be cause for concern when taken with 1 or more of the chemotherapy medications they were receiving. Many patients took multiple supplements of potential concern. Of these women, 42% (n=33) consulted with a conventional provider and 24% (n=19) consulted with a CAM provider about the contraindicated supplements they used. CONCLUSION: Although it is not clear that any of these contraindicated combinations of CAM and conventional therapy actually caused adverse outcomes, increased toxicities, or reduced the effectiveness of primary therapies, all these effects are possible given the substances being used in combination. Research is needed to understand the real risk associated with CAM and conventional polypharmacy. If risks associated with CAM use prove substantial, then improved systems to assure that all women get advice regarding supplement use during ovarian cancer treatment will be needed.
OBJECTIVE: Some ingestible complementary and alternative medicine (CAM) supplements, including herbal remedies, teas, and vitamins, have biological activities that make them likely to interact poorly with conventional chemotherapeutic treatments. This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together. METHODS: A total of 219 patients with ovarian cancer who received care from 1 of 2 participating conventional oncology practices were surveyed about CAM use during and after ovarian cancer treatment. RESULTS: A total of 200 women reported having chemotherapy to treat their ovarian cancer. Of those, 79 (40%) reported using 1 or more CAM supplements that could be cause for concern when taken with 1 or more of the chemotherapy medications they were receiving. Many patients took multiple supplements of potential concern. Of these women, 42% (n=33) consulted with a conventional provider and 24% (n=19) consulted with a CAM provider about the contraindicated supplements they used. CONCLUSION: Although it is not clear that any of these contraindicated combinations of CAM and conventional therapy actually caused adverse outcomes, increased toxicities, or reduced the effectiveness of primary therapies, all these effects are possible given the substances being used in combination. Research is needed to understand the real risk associated with CAM and conventional polypharmacy. If risks associated with CAM use prove substantial, then improved systems to assure that all women get advice regarding supplement use during ovarian cancer treatment will be needed.
Authors: Elizabeth M Swisher; David E Cohn; Barbara A Goff; Judy Parham; Thomas J Herzog; Janet S Rader; David G Mutch Journal: Gynecol Oncol Date: 2002-03 Impact factor: 5.482
Authors: Lucy K Helyer; Stephen Chin; Betty K Chui; Barbara Fitzgerald; Sunil Verma; Eileen Rakovitch; George Dranitsaris; Mark Clemons Journal: BMC Cancer Date: 2006-02-21 Impact factor: 4.430
Authors: Terry E Lopez; Hoang M Pham; Julia Barbour; Phillip Tran; Benjamin Van Nguyen; Sean P Hogan; Richelle L Homo; Volkan Coskun; Samuel E Schriner; Mahtab Jafari Journal: J Funct Foods Date: 2016-01-01 Impact factor: 4.451
Authors: Richard T Lee; Andrea Barbo; Gabriel Lopez; Amal Melhem-Bertrandt; Heather Lin; Olufunmilayo I Olopade; Farr A Curlin Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Erin Sweet; Fred Dowd; May Zhou; Leanna J Standish; M Robyn Andersen Journal: Evid Based Complement Alternat Med Date: 2016-07-26 Impact factor: 2.629